Rapid animal colony development: crucial to effective pre-clinical drug development

21 November 2018
envigo_large

The success of any pre-clinical research program relies on selecting the right animal for a study, writes Emmanuel Gomas, European services manager at Envigo, in an expert view piece.

But the timing and availability of an animal research colony represents a major challenge for researchers and facility managers alike. Researchers must ensure they can rapidly expand or contract their colony and generate the appropriate number of study cohorts.

Consequently, effective colony development and cohort supply strategies are needed to enable access to a reliable and flexible supply of models, and to keep experimental programs on track.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical